Skip to content

Inventories at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
$10.46M+52.7%
Guardant Health logo
Guardant HealthGH
$83.85M+8.5%
Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
$382K-16.8%
GeneDx Holdings logo
GeneDx HoldingsWGS
$12.24M-3.3%
Quest Diagnostics logo
Quest DiagnosticsDGX
$225M+19.0%
Labcorp Holdings logo
Labcorp HoldingsLH
$497.7M+1.9%

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's inventories?
Lucid Diagnostics (LUCD) reported inventories of $469K in Q1 2026.
How has Lucid Diagnostics's inventories changed year-over-year?
Lucid Diagnostics's inventories decreased by 3.1% year-over-year, from $484K to $469K.
What is the long-term trend for Lucid Diagnostics's inventories?
Over 3 years (2022 to 2025), Lucid Diagnostics's inventories has grown at a 47.1% compound annual growth rate (CAGR), from $111K to $353K.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.